Get all your news in one place.
100’s of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
National
Karl Matchett

What AstraZeneca could cost London stock market if it moves to US

  • AstraZeneca's CEO, Pascal Soriot, has reportedly held private discussions about moving the pharmaceutical firm's stock market listing from London to the US.
  • The potential move is primarily driven by the CEO's long-standing frustrations with UK regulations, including restrictions on new medicines and pricing structures.
  • Such a shift would represent a significant blow to the London Stock Exchange, as AstraZeneca is currently its largest listed company with a market capitalisation exceeding £161bn.
  • The US is AstraZeneca's largest revenue source, contributing $21.8bn (£15.3bn) of its $54bn (£39bn) total revenue in 2024, highlighting the market's importance to its growth strategy.
  • The company previously abandoned plans for a £450m vaccine hub near Liverpool, citing “timing” and a funding gap, amid ongoing discussions with the UK government regarding pharmaceutical industry support.

IN FULL

Fears over £160bn blow to London’s stock market as AstraZeneca considers listing move to US

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.